"Only by continuously deepening the integration of basic and translational research can we continue to promote the high-quality development of hematology, let more patients with blood diseases welcome the hope of cure, and contribute Chinese wisdom and Chinese programs to the development of global hematology." Cheng Tao, an academician of the CAE Member, president of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology of the Chinese Academy of Medical Sciences), and executive deputy director of the Cell Ecology Haihe Laboratory, said recently at the 6th China Hematology Development Conference. This conference is a grand event for China's hematology department in the first year of the 15th Five Year Plan. Many scholars attended and gave presentations, showcasing the achievements of China's hematology department in basic research and clinical translation. Source innovation leading international basic research is the source of vitality for the development of hematology. In 2020, Cheng Tao proposed the concept of "blood ecology", which shifts the traditional static research paradigm of the blood system to a system cognition of dynamic correlation, laying a theoretical foundation for interdisciplinary research. Nowadays, this concept has taken root and helped China to enter the international forefront in basic research fields such as hematopoietic development and maintenance of hematopoietic homeostasis, especially in the analysis of hematopoietic stem cell transplantation mechanisms, origin and differentiation, which are at the forefront of the world. Chinese scholars continue to make breakthroughs in the study of disease mechanisms. ”Zhang Lei, Vice President of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), introduced that his research team has discovered potential new targets such as CD38 monoclonal antibodies for immune thrombocytopenia, bringing new hope to patients with refractory recurrence. In addition, the application of single-cell spatiotemporal multi omics technology has established a multi omics queue of immune cells in the Chinese population, achieving multimodal data fusion from genes to pathological models, and providing support for precise diagnosis and treatment. Statistics show that from 2020 to 2024, the total number of SCI papers in the field of hematological diseases in China reached 25058, an increase of 2.18 times compared to the previous five years, and the research strength has significantly improved. The breakthrough in basic research in hematology is accelerating its translation into clinical effectiveness. For example, the hemophilia B gene therapy drug "Xinjiuning" developed by Zhang Lei's team has become the first gene therapy drug to be unconditionally launched in Asia, bringing good news to patients. Shi Jun, Deputy Director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), introduced that gene therapy for thalassemia has also made significant progress. Slow virus vectors and CRISPR-Cas9 technology have enabled more than 90% of patients to achieve clinical cure, and related research is expected to enter phase II clinical trials by 2026. At the same time, policy dividends and collaborative mechanisms continue to empower the transformation of basic research. At present, the Chinese Hematology Specialty Alliance has absorbed 167 member units to promote the sinking of high-quality resources. During the 14th Five Year Plan period, the number of patent authorizations in the field of hematological diseases in China increased sixfold, 28 innovative drugs were launched, 866 clinical trial projects were implemented, forming a full chain innovation model of "basic research patent protection clinical transformation industrial landing". Cheng Tao specifically mentioned that the "Regulations on the Administration of Clinical Research and Clinical Translational Application of Biomedical New Technologies" (also known as "Order 818") issued by the State Council will be implemented on May 1st this year, which will provide a solid institutional guarantee for the healthy development of the cell and gene therapy industry. Looking towards the future, Cheng Tao proposed to focus on cutting-edge technological breakthroughs, strive to create a national blood biological sample bank, and establish a multi center queue and big data center; Strengthen the integration of artificial intelligence and hematology, and promote the research and development of artificial intelligence assisted pathological diagnosis; Expand the research scope of "big blood" and extend the advantages of hematology to fields such as cardiovascular and autoimmune diseases. The conference also released important information in the field of hematology for 2025 and the results of the selection of the top ten research advances in Chinese hematology for 2025. The attending scholars stated that from the "source innovation" of basic research to the "landing effect" of clinical translation, from the development of a single discipline to the ecological prosperity of "government industry university research application", the Chinese hematology discipline will empower the construction of a healthy China with high-quality development. (New Society)